How AI Is Transforming Medical Affairs for Indian Pharma Companies

The Medical Affairs Challenge in Indian Oncology

If you run a medical affairs team at an Indian pharma company with oncology products, your week probably looks something like this. Your MSLs are trying to get 15-minute slots with oncologists who are seeing 30+ patients a day. Your medical information team is fielding requests that take 48–72 hours to turn around. Your scientific content was approved three months ago and is already missing two major guideline updates. And your engagement metrics show that doctors open your emails about 12% of the time.

This is not a uniquely Indian problem, but India has some unique complications. The oncology market here is projected to grow by USD 2 billion between 2025 and 2029, at a CAGR of 19.8%. New cancer cases are expected to exceed 1.57 million annually by 2025. Hospital chains like Apollo, Fortis, Max Healthcare, and HCG are expanding their oncology departments aggressively—Apollo now has 13 cancer centres across 12 cities, and Fortis reports oncology contributing 16.4% of hospital revenue. There are more oncologists to reach, more products to support, and more evidence to disseminate than ever before.

Meanwhile, the regulatory environment is tightening. UCPMP 2024 has made compliance-first engagement non-negotiable. Every interaction, every piece of content, every touchpoint with an HCP must be traceable, truthful, and balanced. The days of relationship-based selling masquerading as medical affairs are over.

What Indian Oncologists Actually Want

Bain & Company research found that Indian doctors overwhelmingly prefer communication via WhatsApp, with click rates 3.5 times higher than email. Scientific content—publication findings, clinical case studies, real-world evidence—generated up to 2.5 times higher engagement than promotional content. Short video content outperformed articles by 3.5 times.

The message is clear: oncologists in India do not want more sales pitches. They want clinical intelligence delivered fast, on the channels they already use, in formats they can consume between patient consultations. They want to know what the latest NCCN guideline update means for their NSCLC patients. They want drug interaction data for the specific combination regimen they are prescribing. They want biomarker interpretation that goes beyond what the lab report says.

This is the gap that AI-powered medical affairs can fill.

How AI Changes the Medical Affairs Workflow

Evidence Synthesis That Keeps Pace

The biggest bottleneck in pharma medical affairs is the lag between when evidence is published and when it reaches oncologists in a usable format. A landmark study comes out, and it takes weeks for your medical affairs team to create compliant summaries, route them through MLR review, and push them through field teams.

An AI-powered clinical evidence platform can continuously monitor oncology literature, extract key findings, and present them in formats that oncologists can actually use at the point of care. When an oncologist queries the platform about treatment options for stage IIIB NSCLC with an EGFR mutation, they get a synthesized answer that reflects the latest published evidence, current NCCN and ESMO guidelines, and relevant real-world data—not a slide deck from last quarter.

Platforms like OneRx are built for exactly this use case. OneRx’s Evidence Intelligence module continuously curates oncology evidence, and its Treatment Planning feature helps oncologists navigate complex treatment decisions with current guideline support. For pharma medical affairs teams, this means your MSLs walk into meetings armed with evidence that is days old, not months old.

Doctor Engagement That Passes the UCPMP Test

Under UCPMP 2024, every piece of content shared with an HCP must be truthful, balanced, and verifiable. Generic promotional emails fail this test. An AI-informed engagement approach identifies what clinical questions a specific oncologist is likely facing—based on their specialty, patient population, and the therapeutic area—and delivers relevant evidence through their preferred channel.

This is not omnichannel marketing dressed up in new language. This is genuinely useful content reaching the right doctor at the right time. When your platform can tell you that an oncologist in Bengaluru has been querying drug interaction data for a specific combination regimen, your MSL can follow up with relevant published evidence on that exact topic. That is doctor engagement pharma teams have been chasing for years.

Real-World Evidence at Scale

Real-world evidence in pharma is no longer a nice-to-have—it is a regulatory and commercial imperative. Indian pharma companies like Sun Pharma, Cipla, and Dr. Reddy’s are investing in real-world data capabilities. AI platforms that can analyze treatment patterns, outcome data, and adverse event signals across patient populations turn raw data into the kind of clinical intelligence that medical affairs teams need.

OneRx’s platform captures clinical queries and usage patterns that can inform real-world evidence generation. When thousands of oncologists use the platform to check drug interactions or review staging criteria, the aggregate data provides insights into prescribing patterns and clinical information needs that no survey or advisory board can match.

What This Looks Like for a Medical Affairs Team

Imagine your company has just received DCGI approval for a new targeted therapy for HER2+ breast cancer. In the traditional model, you would create a launch deck, train your MSLs over two weeks, and begin scheduling KOL meetings across metros. Six weeks later, maybe 40% of target oncologists have received a face-to-face update.

In the AI-augmented model, the evidence is available on a clinical intelligence platform from day one. Oncologists querying treatment options for HER2+ breast cancer encounter the new evidence organically. Your MSLs can see which oncologists have engaged with the data and follow up with personalised, UCPMP-compliant conversations. Your medical information team handles fewer reactive queries because the platform has already answered the most common clinical questions. Your engagement is broader, faster, compliant, and—most importantly—useful to the doctor.

The Strategic Opportunity

India’s pharma industry is expected to reach USD 130 billion by 2030. Within that, oncology is the fastest-growing therapeutic segment. The companies that invest in AI-powered medical affairs now—not as a digital experiment, but as a core capability—will build relationships with oncologists that their competitors cannot replicate with field force alone.

This is not about replacing MSLs with software. It is about giving your medical affairs team an AI-powered co-pilot that ensures every interaction with an oncologist is informed by the latest evidence, tailored to their clinical needs, and compliant with UCPMP 2024 from the start.

The oncologists are already looking for tools like this. The question is whether your medical affairs team will be the one that brings it to them.